Healthcare / Medical Instruments & SuppliesTaiwan
$55.00
-1.90 (-3.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-238.0M · quality 25.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
9/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.3%
↓Gross Margin
34.1%
↓Debt/Equity
1.75
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-6.0%
FCF CAGR
—
FCF margin
11.2%
FCF / Net income
-1.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.84B · net income $-180.3M · FCF $206.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.84B | $1.84B | $1.93B | $1.76B | $2.21B |
| Net Income | $-180.3M | $-180.3M | $-127.2M | $6.2M | $91.0M |
| EBITDA | $-2.2M | $-2.2M | $59.3M | $179.8M | $270.4M |
| EPS | — | — | -1.88 | 0.09 | 1.33 |
| Gross Margin | 34.1% | 34.1% | 39.7% | 40.8% | 45.4% |
| Operating Margin | -11.1% | -11.1% | -6.7% | -2.8% | 7.3% |
| Net Margin | -9.8% | -9.8% | -6.6% | 0.4% | 4.1% |
| Balance Sheet | |||||
| Debt/Equity | 1.75 | 1.75 | 1.68 | 1.42 | 1.10 |
| Current Ratio | 0.85 | 0.85 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $206.4M | $206.4M | $-313.3M | $-238.0M | $-170.6M |
| Returns | |||||
| ROE | -10.3% | -10.3% | -6.8% | 0.3% | 4.4% |
| Valuation | |||||
| P/E | — | — | — | 742.17 | 52.88 |
| EV/EBITDA | — | — | 114.05 | 38.78 | 25.38 |
| P/B | 2.14 | 2.14 | 2.08 | 2.29 | 2.32 |
| Growth & Yield | |||||
| Revenue Growth | -4.9% | -4.9% | 10.1% | -20.6% | — |
| EPS Growth | — | — | -2189.7% | -93.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.88 → n/d
Residual
-11.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.